{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:50:32Z","timestamp":1790178632491,"version":"4.1.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.clml.2020.04.012","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T16:28:49Z","timestamp":1588609729000},"page":"e543-e546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Impact of an Oncology Clinical Pharmacist Specialist in an Outpatient Multiple Myeloma Clinic"],"prefix":"10.1016","volume":"20","author":[{"given":"Amin","family":"Virani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Schlei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Gleason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"McIver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J.","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagoda","family":"Jasielec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Parsad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.04.012_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1200\/JOP.0723601","article-title":"Future supply and demand for oncologists: challenges to assuring access to oncology services","volume":"3","author":"Erikson","year":"2007","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clml.2020.04.012_bib4","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/1078155215608523","article-title":"Impact of oncology pharmacist\u2013managed oral anticancer therapy in patients with chronic myelogenous leukemia","volume":"22","author":"Lam","year":"2016","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2020.04.012_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/JOP.2010.000033","article-title":"Pharmacist-led, interdisciplinary model for delivery of supportive care in the ambulatory cancer clinic setting","volume":"6","author":"Valgus","year":"2010","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clml.2020.04.012_bib6","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/ajhp\/58.12.1126","article-title":"Practical approach to determining costs and frequency of adverse drug events in a health care network","volume":"58","author":"Senst","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clml.2020.04.012_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jama.1997.03540280039031","article-title":"Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality","volume":"277","author":"Classen","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2020.04.012_bib8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jama.1997.03540280045032","article-title":"The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group","volume":"277","author":"Bates","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2020.04.012_bib9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.282.3.267","article-title":"Pharmacist participation on physician rounds and adverse drug events in the intensive care unit","volume":"282","author":"Leape","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2020.04.012_bib10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1592\/phco.19.8.556.31531","article-title":"Clinical pharmacy services and hospital mortality rates","volume":"19","author":"Bond","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clml.2020.04.012_bib11","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/archinte.159.19.2306","article-title":"A\u00a0prospective, randomized trial to assess the cost impact of pharmacist-initiated interventions","volume":"159","author":"McMullin","year":"1999","journal-title":"Arch Intern Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502030207X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502030207X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:22Z","timestamp":1761870862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502030207X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S215226502030207X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of an Oncology Clinical Pharmacist Specialist in an Outpatient Multiple Myeloma Clinic","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}